These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35695279)

  • 41. Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
    Surjan J; Grossi JD; Del Porto JA; Delfino RS; de Oliveira Cerqueira R; Lucchese AC; Magalhães E; Del Sant LC; Tuena MA; Nakahira C; Fava VAR; Steglich MS; Abdo GL; Barbosa MG; Sarin LM; Lacerda ALT
    Clin Drug Investig; 2022 Oct; 42(10):865-873. PubMed ID: 36044154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
    Di Vincenzo JD; Lipsitz O; Rodrigues NB; Jones BDM; Gill H; Lee Y; Lui LMW; Teopiz KM; Ho R; Lin K; Nasri F; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2022 Jan; 307():114321. PubMed ID: 34890909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.
    Zheng W; Gu LM; Yang XH; Zhou YL; Wang CY; Lan XF; Zhang B; Ning YP
    Int J Psychiatry Clin Pract; 2023 Jun; 27(2):145-150. PubMed ID: 36309806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
    J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
    Correia-Melo FS; Leal GC; Vieira F; Jesus-Nunes AP; Mello RP; Magnavita G; Caliman-Fontes AT; Echegaray MVF; Bandeira ID; Silva SS; Cavalcanti DE; Araújo-de-Freitas L; Sarin LM; Tuena MA; Nakahira C; Sampaio AS; Del-Porto JA; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    J Affect Disord; 2020 Mar; 264():527-534. PubMed ID: 31786030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
    Anand A; Mathew SJ; Sanacora G; Murrough JW; Goes FS; Altinay M; Aloysi AS; Asghar-Ali AA; Barnett BS; Chang LC; Collins KA; Costi S; Iqbal S; Jha MK; Krishnan K; Malone DA; Nikayin S; Nissen SE; Ostroff RB; Reti IM; Wilkinson ST; Wolski K; Hu B
    N Engl J Med; 2023 Jun; 388(25):2315-2325. PubMed ID: 37224232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
    Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
    Swainson J; McGirr A; Blier P; Brietzke E; Richard-Devantoy S; Ravindran N; Blier J; Beaulieu S; Frey BN; Kennedy SH; McIntyre RS; Milev RV; Parikh SV; Schaffer A; Taylor VH; Tourjman V; van Ameringen M; Yatham LN; Ravindran AV; Lam RW
    Can J Psychiatry; 2021 Feb; 66(2):113-125. PubMed ID: 33174760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP
    J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review.
    Sakurai H; Jain F; Foster S; Pedrelli P; Mischoulon D; Fava M; Cusin C
    J Affect Disord; 2020 Nov; 276():660-666. PubMed ID: 32871698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Replication of distinct trajectories of antidepressant response to intravenous ketamine.
    O'Brien B; Lee J; Kim S; Nandra GS; Pannu P; Swann AC; Murphy N; Tamman AJF; Amarneh D; Lijffijt M; Averill LA; Mathew SJ
    J Affect Disord; 2023 Jan; 321():140-146. PubMed ID: 36302492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
    Feeney A; Hock RS; Freeman MP; Flynn M; Hoeppner B; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Fava M; Papakostas GI
    Eur Neuropsychopharmacol; 2021 Aug; 49():122-132. PubMed ID: 34090255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
    Rodrigues NB; Siegel A; Lipsitz O; Cha DS; Gill H; Nasri F; Simonson K; Shekotikhina M; Lee Y; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; McIntyre RS; Rosenblat JD
    CNS Spectr; 2022 Jun; 27(3):315-321. PubMed ID: 33298225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.